Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT
October 22, 2024 02:00 ET
|
Epicrispr Biotechnologies
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Epicrispr Biotechnologies, a leading epigenetic editing company, presented new data on its hypercompact platform for epigenetic...
Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress
June 07, 2024 08:00 ET
|
Epic Bio
Epic Bio to present highlights of IND-enabling data package for lead candidate EPI-321 in FSHD at FSHD International Research Congress.
Epic Bio to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
May 23, 2024 08:00 ET
|
Epic Bio
Amber Salzman, Ph.D., Epic Bio chief executive officer, will participate in a fireside chat at Stifel’s 2nd Annual Genetic Medicines Forum.
Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
April 23, 2024 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of...
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
April 10, 2024 13:47 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that...
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
April 09, 2024 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the...
Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium
April 01, 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
March 13, 2024 16:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
November 21, 2023 12:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
November 16, 2023 06:00 ET
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...